1.
Pakistan Journal of Medical Sciences. 2013; 29 (5): 1278-1279
Dans Anglais
| IMEMR
| ID: emr-193711
Résumé
Lung cancer is currently one of the leading causes of the cancer-related deaths in the world. Erlotinib and Gefitinib are inhibitors of human epidermal growth factor receptor-1 and the epidermal growth factor receptor tyrosine kinase. The most common adverse events for erlotinib and gefitinib were mild to moderate skin toxicity [rash, itching, and dry skin], gastrointestinal reactions [diarrhea and nausea], and fatigue. Erlotinib induced gastrointestinal bleeding is rare, and dose-related. We are reporting a lung cancer patient who received erlotinib and gefitinib. The patient was sensitive to drug and tumor growth was inhibited. However, adverse reactions appeared as drug treatment continued, including gastrointestinal bleeding